AzTrials
AzTrials

AnxietyPhase 4NCT02177955

Comparative Study of Hemodynamic Changes Caused by Diazepam and Midazolam During Third Molar Surgery

A Phase 4 study testing 7.5 mg Midazolam and 10 mg diazepam in people with Anxiety, run by Jimmy Barbalho at 1 site in Brazil.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Objective: The aim of the present study was to compare hemodynamic changes using 7.5 mg of midazolam and 10.0 mg of diazepam during the surgical removal of symmetrically positioned third molars. Read more about this study

Who is it for?
Ages 18 to 40 yearsHealthy volunteers can take part
Conditions the study is for
Anxiety
What is being tested?
7.5 mg Midazolam and 10 mg diazepam
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
120 participants
Where
1 siteBrazil
Study dates
Jan 2011to Sep 2012
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • The inclusion criteria were classification in Group 1 of the American Society of Anesthesiology (normal healthy patient with no adverse systemic condition or continuous use of medication) and no self-reported reactions or allergies to the drugs employed in the study

Who cannot join

  • The exclusion criteria were refusal to participate after reading the statement of informed consent, self-reported allergy to the drugs employed and failure to return for the second surgery on the contralateral side

Trial locations and contacts

1 site in 1 country.

Brazil1 site
  • School of Dentistry of Pernambuco

    Recife, Pernambuco, 54756220

Other trials in Brazil

About this study

Official title: Comparative Study of Hemodynamic Changes Caused by Diazepam and Midazolam During Third Molar Surgery. A Prospective Randomized Study

Objective: The aim of the present study was to compare hemodynamic changes using 7.5 mg of midazolam and 10.0 mg of diazepam during the surgical removal of symmetrically positioned third molars.

Study design: A prospective, randomized, double-blind, clinical trial was carried out involving 120 patients divided in three groups: Group 1 (diazepam and placebo), Group 2 (midazolam and placebo) and Group 3 (diazepam and midazolam). Each subject underwent two surgeries on separate occasions under local anesthesia.

Read the detailed description

Study design A double-blind, randomized, crossover, clinical trial with a split-mouth design was carried out. This study received approval from the Human Research Ethics Committee of the institution at which it was carried out (process number: 001.0.097.000-08) and was conducted in compliance with the Consolidated Standards of Reporting Trials (CONSORT) statement. All patients signed a statement of informed consent agreeing to participate in the study.

Sample size and pilot study The sample size was estimated using the a computational program. Thirty patients were submitted to third molar surgeries in a pilot study to determine the sample size. This step was necessary due to the lack of similar studies in the literature. Calculations were performed with specific programs taking into consideration the variables, a 95% confidence interval, 80% test power and 5% error. At the end of the study, 120 patients were analyzed (40 in each group), totaling 240 surgeries.

Sample selection One hundred twenty eight individuals between 18 and 40 years of age were selected for participation in the present study and submission to maxillary and mandibular third molar extractions bilaterally at the Department of Oral-Maxillofacial Surgery. Each patient was to be submitted to two surgeries. The third molars (maxillary or mandibular) needed to have the same degree of impaction on both sides.

Three groups were formed: Group A received diazepam and placebo, Group B received midazolam and placebo and Group C received midazolam and diazepam. For the purposes of randomization and blinding of the surgeon and researcher in charge of analyzing the results, the groups were renominated Groups 1, 2 and 3. The randomization procedure was carried out by a researcher who was not directly involved in the surgeries or evaluations. Sequentially numbered, sealed, opaque envelopes were used, each containing a combination of substances and the side to be submitted to the first surgery. For each patient, the researcher opened an envelope, informed the main investigator and surgeon of the side to be operated, and administered the substance to the patient. The second surgery was performed on the contralateral side with the administration of the second substance. Blinding was performed to avoid awareness regarding what substance was administered in each surgery. For such, the pills were fabricated with the same outer color and a standardized size at the Pernambuco Pharmaceutical Laboratory (Brazil) and were packaged in recipients with the same color. The recipients were denominated 1, 2 and 3.

Surgical procedures and medications As the patients were classified as healthy, no prophylactic use of antibiotics was performed prior to surgery for the prevention of bacterial endocarditis, as recommended by the American Heart Association. All patients rinsed their mouths with 0.12% chlorhexidine for one minute prior to surgery to reduce the bacterial population in the oral cavity. Moreover, all patients were instructed to take two 4-mg pills of dexamethasone one hour prior to surgery. The use of a corticosteroid in the preoperative period minimizes the occurrence of postoperative swelling and reduces the risk of trismus.13 The substances (diazepam, midazolam and placebo) were administered orally 45 minutes prior to the surgical procedure. As the substances were masked, neither the surgeon nor the patient was aware of what substance was given (double-blind study).

Conditions
Anxiety
Being tested
7.5 mg Midazolam, 10 mg diazepam
Keywords
Third Molar, Anty-anxiety drugs, hemodynamic, Benzodiazepines
Medical subject headings
Anxiety Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 7.5 mg MidazolamDrug

    7.5 mg midazolam 45 minutes before surgery

  • 10 mg diazepamDrug

    10 mg midazolam 45 minutes before surgery

Study groups in NCT02177955
Study groupRoleWhat they receive
midazolanPlacebo comparator7.5 mg midazolan 45 minutes before the surgery
Receives: Drug: 7.5 mg Midazolam
diazepamPlacebo comparator10 mg diazepam 45 minutes before the surgery
Receives: Drug: 10 mg diazepam

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes from baseline in systolic blood pressure until the end of surgery

    Measured: baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery.

  2. Changes from baseline in diastolic blood pressure until the end of surgery

    Measured: Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery

  3. Changes from baseline in mean blood pressure until the end of surgery

    Measured: Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery

  4. Changes from baseline in heart rate until the end of surgery

    Measured: Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery

  5. Changes from baseline in rate pressure product until the end of surgery

    The rate pressure is the product of the multiplication of systolic blood pressure by heart rate

    Measured: Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery

  6. Changes from baseline in oxygen saturation until the end of surgery

    Measured: Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery

  7. Change from baseline in pressure rate quotient until the end of surgery

    Pressure rate quotient is calculated by dividing mean blood pressure by heart rate

    Measured: Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Jun 2014 (estimated)
  2. Study startJan 2011
  3. Primary completionJul 2012
  4. Study completionSep 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
120 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02177955
Sponsor's protocol ID
001.0.097.000-08
Other IDs
001.0.097.000-08
Status last verified
Jun 2014
First submitted
21 Jun 2014
Last updated
30 Jun 2014
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing 7.5 mg Midazolam and 10 mg diazepam in people with Anxiety, run by Jimmy Barbalho at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Jun 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes from baseline in systolic blood pressure until the end of surgery (time frame: baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery.). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jun 2014; AzTrials last refreshed its copy on 1 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in